Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ingrid Meszoely, MD
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University
Atlanta, Georgia, United States
- Surgical Associates, Inc.
Tulsa, Oklahoma, United States
- Allegheny Cancer Center
Pittsburgh, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center, One Hundred Oaks
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2008
- Primary completion
- 30 Sept 2018
- Completion
- 30 Sept 2018
- Last update posted
- 15 Oct 2018
- Registered enrollment
- 213
- Registry id
- NCT00651976
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.